Skip to main content

Table 4 Univariate and Multivariate Cox Regression for OS of breast cancer with liver metastases at diagnosis in the SEER database

From: Risk and prognostic factors of breast cancer with liver metastases

Variable Overall Survival
Univariable Multivariable
HR (95% CI) P Value HR (95% CI) P Value
Age, y
 18–40 1[Reference]   1[Reference]  
 41–60 1.52 (1.32–1.76) < 0.001* 1.39 (1.20–1.61) < 0.001*
 61–80 2.17 (1.88–2.51) < 0.001* 1.84 (1.58–2.15) < 0.001*
  > 80 4.44 (3.65–5.39) < 0.001* 3.62 (2.76–4.74) < 0.001*
Race a
 White 1[Reference]   1[Reference]  
 Black 1.21 (1.09–1.33) < 0.001* 1.35 (1.22–1.50) < 0.001*
 Hispanic 0.99 (0.87–1.13) 0.895 1.16 (1.02–1.32) 0.028*
 Asian or Pacific Islander 0.86 (0.74–1.02) 0.078 0.90 (0.76–1.05) 0.182
 American Indian or Alaska Native 0.96 (0.58–1.59) 0.869 1.01 (0.60–1.68) 0.984
 Unknown 0.34 (0.09–1.37) 0.129 0.28 (0.07–1.15) 0.078
Marital status
 Unmarried a 1[Reference]   1[Reference]  
 Married 0.75 (0.70–0.82) < 0.001* 0.84 (0.77–0.91) < 0.001*
 Unknown 0.96 (0.81–1.14) 0.664 0.89 (0.75–1.06) 0.200
Insurance status
 Uninsured b 1[Reference]   1[Reference]  
 Insured 0.75 (0.62–0.91) 0.003* 0.71 (0.59–0.86) < 0.001*
 Unknown 0.94 (0.68–1.30) 0.717 0.83 (0.57–1.22) 0.348
Histology
 Infiltrating duct carcinoma 1[Reference]   1[Reference]  
 Lobular carcinoma 1.14 (0.97–1.34) 0.112 0.87 (0.74–1.03) 0.101
 Infiltrating duct and lobular carcinoma 0.94 (0.68–1.30) 0.717 0.89 (0.70–1.13) 0.323
 Other types c 1.43 (1.30–1.58) < 0.001* 1.18 (1.05–1.33) 0.005*
Pathological Grade
 I 1[Reference]   1[Reference]  
 II 1.08 (0.86–1.37) 0.515 1.35 (1.07–1.72) 0.013*
 III/IV 1.30 (1.04–1.64) 0.022* 1.69 (1.34–2.14) < 0.001*
 Unknown 1.59 (1.26–1.01) < 0.001* 1.59 (1.23–2.05) < 0.001*
Surgery of primary site
 Yes 1[Reference]   1[Reference]  
 No 1.72 (1.56–1.89) < 0.001* 1.52 (1.38–1.68) < 0.001*
 Unknown 0.93 (0.62–1.38) < 0.001* 0.96 (0.64–1.43) < 0.001*
Radiotherapy
 Yes 1[Reference]   1[Reference]  
 No/Unknown 1.03 (0.94–1.12) 0.528 0.95 (0.87–1.04) 0.270
Chemotherapy
 Yes 1[Reference]   1[Reference]  
 No/Unknown 2.03 (1.87–2.20) < 0.001* 1.63 (1.50–1.78) < 0.001*
Extrahepatic metastatic sites to lung, brain and bone, No
 0 1[Reference]   1[Reference]  
 1 1.49 (1.34–1.65) < 0.001* 1.42 (1.28–1.58) < 0.001*
 2 1.94 (1.73–2.18) < 0.001* 1.85 (1.65–2.09) < 0.001*
 All 3 2.94 (2.44–3.56) < 0.001* 3.43 (2.77–4.26) < 0.001*
 Unknown 1.92 (1.62–2.28) < 0.001* 1.62 (1.36–1.93) < 0.001*
Subtype
 HR+/HER2− 1[Reference]   1[Reference]  
 HR+/HER2+ 0.59 (0.53–0.66) < 0.001* 0.69 (0.61–0.77) < 0.001*
 HR−/HER2+ 0.72 (0.63–0.82) < 0.001* 0.85 (0.74–0.97) 0.014*
 Triple-negative 2.10 (1.88–2.35) < 0.001* 2.46 (2.18–2.77) < 0.001*
 Unknown 1.54 (1.36–1.74) < 0.001* 1.38 (1.20–1.58) < 0.001*
  1. Notes: a including divorced, separated, single (never married), and widowed; b including insured, Insured/No specifics Any Medicaid; c including other histology of invasive breast cancer except Infiltrating duct carcinoma, Lobular carcinoma and Infiltrating duct and lobular carcinoma;
  2. + denotes positive; − denotes negative; * denotes a statistically significant P-value; HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, OR Odds ratio, CI Confidence interval